CABG plus medical therapy reduced death from any cause compared to medical therapy alone (HR 0.73; 95% CI 0.60-0.90), with no significant interaction based on myocardial viability (P=0.34).
RCT (n=601)
Randomized
Does CABG plus medical therapy reduce death from any cause compared to medical therapy alone in patients with ischemic cardiomyopathy, and is this benefit dependent on myocardial viability?
In patients with ischemic cardiomyopathy, CABG improves long-term survival compared to medical therapy alone regardless of myocardial viability, challenging the utility of viability testing for selecting patients for surgical revascularization.
Effect estimate: HR 0.73 (95% CI 0.60-0.90)
Absolute Event Rate: 61.1% vs 69%
BACKGROUND: The role of assessment of myocardial viability in identifying patients with ischemic cardiomyopathy who might benefit from surgical revascularization remains controversial. Furthermore, although improvement in left ventricular function is one of the goals of revascularization, its relationship to subsequent outcomes is unclear. METHODS: Among 601 patients who had coronary artery disease that was amenable to coronary-artery bypass grafting (CABG) and who had a left ventricular ejection fraction of 35% or lower, we prospectively assessed myocardial viability using single-photon-emission computed tomography, dobutamine echocardiography, or both. Patients were randomly assigned to undergo CABG and receive medical therapy or to receive medical therapy alone. Left ventricular ejection fraction was measured at baseline and after 4 months of follow-up in 318 patients. The primary end point was death from any cause. The median duration of follow-up was 10.4 years. RESULTS: CABG plus medical therapy was associated with a lower incidence of death from any cause than medical therapy alone (182 deaths among 298 patients in the CABG group vs. 209 deaths among 303 patients in the medical-therapy group; adjusted hazard ratio, 0.73; 95% confidence interval, 0.60 to 0.90). However, no significant interaction was observed between the presence or absence of myocardial viability and the beneficial effect of CABG plus medical therapy over medical therapy alone (P = 0.34 for interaction). An increase in left ventricular ejection fraction was observed only among patients with myocardial viability, irrespective of treatment assignment. There was no association between changes in left ventricular ejection fraction and subsequent death. CONCLUSIONS: The findings of this study do not support the concept that myocardial viability is associated with a long-term benefit of CABG in patients with ischemic cardiomyopathy. The presence of viable myocardium was associated with improvement in left ventricular systolic function, irrespective of treatment, but such improvement was not related to long-term survival. (Funded by the National Institutes of Health; STICH ClinicalTrials.gov number, NCT00023595.).
Panza et al. (Wed,) conducted a rct in Ischemic cardiomyopathy (n=601). CABG plus medical therapy vs. Medical therapy alone was evaluated on Death from any cause (HR 0.73, 95% CI 0.60-0.90). CABG plus medical therapy reduced death from any cause compared to medical therapy alone (HR 0.73; 95% CI 0.60-0.90), with no significant interaction based on myocardial viability (P=0.34).